NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2024 (CONT’D) 5. INVESTMENT IN SUBSIDIARIES (CONT’D) (iv) The summarised financial information (before intra-group elimination) for each subsidiary that has non-controlling interests that are material to the Group is as follows (Cont’d):- MATRIX MEDICARE SDN. BHD. 2024 2023 RM’000 RM’000 At 31 March Non-current assets 29,403 36,331 Current assets 18,587 1,368 Non-current liabilities (39,358) (60,349) Current liabilities (15,430) (30) Net liabilities (6,798) (22,680) Financial Year Ended 31 March Revenue 5,031 – Profit/(Loss) for the financial year/ Total comprehensive income/(expense) 15,882 (4,908) Total comprehensive income/(expense) attributable to non-controlling interests 4,765 (1,472) Net cash flows from/(for) operating activities 8,731 (531) Net cash flows (for)/from financial activities (8,900) 650 6. INVESTMENT IN JOINT VENTURE THE GROUP 2024 2023 RM’000 RM’000 Unquoted shares, at cost 118,800 118,800 Share of post acquisition profits 9,615 10,265 Effect of movement in exchange rate 15,576 14,109 143,991 143,174 The details of the joint venture are as follows:- PRINCIPAL PERCENTAGE PLACE OF OWNERSHIP NAME OF JOINT VENTURE OF BUSINESS 2024 2023 PRINCIPAL ACTIVITIES % % Joint venture of PT Matrix Perkasa Indonesia PT Fin Centerindo Satu @ Indonesia 30 30 Property development @ The joint venture was audited by other firm of chartered accountant. FINANCIAL STATEMENTS 169 INTEGRATED ANNUAL REPORT 2024
RkJQdWJsaXNoZXIy NDgzMzc=